Singapore markets close in 20 minutes
Straits Times Index
3,300.08 +3.19 (+0.10%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,198.27 +26.12 (+0.32%) Bitcoin USD
59,392.41 +1,543.16 (+2.67%) CMC Crypto 200
1,292.18 +15.20 (+1.19%)
ABT Jun 2024 92.500 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:51AM EDT. Market open.
| Previous close | 0.2200 |
| Open | 0.2200 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 92.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.2200 - 0.2200 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksIs Trending Stock Abbott Laboratories (ABT) a Buy Now?
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
ZacksPBH vs. ABT: Which Stock Is the Better Value Option?
PBH vs. ABT: Which Stock Is the Better Value Option?
PR NewswireAbbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
© 2024 Yahoo. All rights reserved.